Form FDA 483 · Issued 2025-09-26
Baxter Oncology GmbH — FDA Form 483 Analysis
FEI: 3002806419 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Drug Manufacturer) · Lead Investigator: Elena R. Rostova
FDA Form 483 issued to Baxter Oncology GmbH (FEI 3002806419) on 2025-09-26 following an inspection of its drug manufacturer operations in Germany. The report documents 3 inspection observations centered on Electronic Record Data Integrity (21 CFR Part 11) & Retention, Incoming Ingredient Identity Testing & COA Qualification.
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 3 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (3)
Observation #1 · 21 CFR 211.46(c)
Electronic Record Data Integrity (21 CFR Part 11) & Retention
FIRST-TIME OBSERVATION
Exhaust systems inadequate to control air contamination
Inspector Observation Language: "Adequate exhaust systems or other systems to control contaminants are lacking in areas where air contamination occurs during production. Specifically, observed during inspection of Baxter Oncology GmbH on 2025-09-26."
Plain-English Meaning: Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window.
Standard CAPA Remediation Path: Enforce unique user credentials, immutable audit trails on analytical instruments, controlled form issuance numbers, and 2-year post-expiration record retention.
Observation #2 · 21 CFR 211.101(d)
Incoming Ingredient Identity Testing & COA Qualification
FIRST-TIME OBSERVATION
Verification of component addition
Inspector Observation Language: "Each component is not added to the batch by one person and verified by a second person.. Specifically, observed during inspection of Baxter Oncology GmbH on 2025-09-26."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.
Observation #3 · 21 CFR 211.160(b)(3)
Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Sampling/testing of drug products
Inspector Observation Language: "The specifications for drug products are deficient in that they do not include a description of the [sampling plan] [testing procedures] for drug products. Specifically, observed during inspection of Baxter Oncology GmbH on 2025-09-26."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.